Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium
Michael P. Randall(Dartmouth College), Michael A. Spinner(Stanford Medicine), Stephanie Meek(Myriad Genetics), William Pearse(University of California San Diego), Joseph M. Tuscano(University of California Davis Medical Center), Mwanasha H. Merrill(Dana-Farber Cancer Institute), Weiyun Z. Ai(City College of San Francisco), David M. Kurtz(Stanford University), Charalambos Andreadis(University of California, San Francisco), Haifaa Abdulhaq(University of California, San Francisco), Carrie Ho(University of California, San Francisco), Chiung‐Yu Huang(I-Shou University), Nicole Foley(University of California, Irvine), Patricia A. Young(University of Maryland, Baltimore County), Wendy Swetzig Dhiman(UCSF Helen Diller Family Comprehensive Cancer Center), Madhav Seshadri(University of California, San Francisco)
Cited by 1
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523